ArticleJournal of ginseng research2021
Effect of coadministration of enriched Korean Red Ginseng (
Article in Journal of ginseng research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01578837 (Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The Effect of Ginseng Supplementation on Lipid Profile: GRADE-assessed Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials.Current pharmaceutical design · 2024Pooled it
- Evaluation of clinical trials of ethnomedicine used for the treatment of diabetes: A systematic review.Frontiers in pharmacology · 2023Pooled it
- The Efficacy of Ginseng (Panax) on Human Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial.European journal of nutrition · 2021Trial
- Prevalence of Reported Dietary Supplement Use in 2019 Older Adult (≥ 55 Years) National Alzheimer's Coordinating Center Participants With Normal Cognition, Mild Cognitive Impairment or Dementia.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Article
- Ginsenoside in the treatment of type 2 diabetes and its complications: a promising traditional chinese medicine.Frontiers in pharmacology · 2025Review
- Effect of ginseng and ginsenosides on attention deficit hyperactivity disorder: A systematic review.Journal of ginseng research · 2024Review
- The beneficial potential of ginseng for menopause.Journal of ginseng research · 2024Review
- Review
- Effects of enzymatic hydrolysis technology on the physicochemical properties and biological activities of American ginseng beverages.Food science & nutrition · 2024Article
- Ginseng extract improves pancreatic islet injury and promotes β-cell regeneration in T2DM mice.Frontiers in pharmacology · 2024Article
- Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Review
- Antidiabetic Properties of Plant Secondary Metabolites.Metabolites · 2023Review
- The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature.Phytotherapy research : PTR · 2022Review
- Article
- Green and Efficient Extraction of Polysaccharide and Ginsenoside from American Ginseng (Molecules (Basel, Switzerland) · 2022Article
- Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development.Frontiers in endocrinology · 2022Review
- Evaluation and Screening of Hypoglycemic Activity of Total Ginsenosides GBE-5 Fraction FromFrontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus and hypertension often occur together, amplifying cardiovascular disease (CVD) risk and emphasizing the need for a multitargeted treatment approach. American ginseng (AG) and Korean Red Ginseng (KRG) species could improve glycemic control via complementary mechanisms. Additionally, a KRG-inherent component, ginsenoside Rg3, may moderate blood pressure (BP). Our objective was to investigate the therapeutic potential of coadministration of Rg3-enriched Korean Red Ginseng (Rg3-KRG) and AG, added to standard of care therapy, in the management of hypertension and cardiometabolic risk factors in type-2 diabetes.
methodsWithin a randomized controlled, parallel design of 80 participants with type-2 diabetes (HbA1c: 6.5-8%) and hypertension (systolic BP: 140-160 mmHg or treated), supplementation with either 2.25 g/day of combined Rg3-KRG + AG or wheat-bran control was assessed over a 12-wk intervention period. The primary endpoint was ambulatory 24-h systolic BP. Additional endpoints included further hemodynamic assessment, glycemic control, plasma lipids and safety monitoring.
resultsCombined ginseng intervention generated a mean ± SE decrease in primary endpoint of 24-h systolic BP (-3.98 ± 2.0 mmHg, p = 0.04). Additionally, there was a greater reduction in HbA1c (-0.35 ± 0.1% [-3.8 ± 1.1 mmol/mol], p = 0.02), and change in blood lipids: total cholesterol (-0.50 ± 0.2 mmol/l, p = 0.01), non-HDL-C (-0.54 ± 0.2 mmol/l, p = 0.01), triglycerides (-0.40 ± 0.2 mmol/l, p = 0.02) and LDL-C (-0.35 ± 0.2 mmol/l, p = 0.06) at 12 wks, relative to control. No adverse safety outcomes were observed.
conclusionCoadministration of Rg3-KRG + AG is an effective addon for improving BP along with attaining favorable cardiometabolic outcomes in individuals with type 2 diabetes. Ginseng derivatives may offer clinical utility when included in the polypharmacy and lifestyle treatment of diabetes. CLINICAL
trial registrationClinicaltrials.gov identifier, NCT01578837.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.